NZ763957B2 - Monospecific and bispecific proteins with immune checkpoint regulation for cancer therapy - Google Patents

Abstract

Provided are monospecific and bispecific proteins that bind specifically to OX40 and/or PD-L1. Exemplary proteins release the inhibition through PD-L1 and stimulate T cell through OX40. Exemplary polyvalent proteins comprise at least one OX40 binding site and at least one PD-L1 binding site. In certain embodiments, the binding sites may be linked through an immunoglobulin constant region. Anti-OX40 and anti-PD-L1 antibodies are also provided.

Description

MONOSPECIFIC AND BISPECIFIC PROTEINS WITH IMMUNE CHECKPOINT REGULATION FOR CANCER THERAPY BACKGROUND Field of Invention The present invention relates to an antibody. More particularly, the present invention relates to the antibody for cancer therapy.

Description of Related Art The two major types of lymphocytes in humans are T (thymus-derived) and B (bone marrow derived. These cells are derived from hematopoietic stem cells in the bone marrow and fetal liver that have committed to the lymphoid development pathway. The progeny of these stem cells follow divergent pathways to mature into either B or T lymphocytes. Human B-lymphocyte development takes place entirely within the bone marrow. T cells, on the other hand, develop from immature precursors that leave the marrow and travel through the bloodstream to the thymus, where they proliferate and differentiate into mature T lymphocytes.

T cells T-cells are the most abundant (about 75% of blood lymphocytes) and potent immune killer cells. The role of effector T-cells in the anti-tumor immune response is strongly supported by in vitro studies and the observation that a high infiltration of CD8+ T cells in several types of tumors correlates with a favorable clinical prognostic (Fridman et al., 2012). The activation of effector naive T-cells requires at least three complementary signals: (i) TCR-CD3/Ag-MHC interaction with the assistance of co-receptors (CD4 or CD8); (ii) binding of co-stimulatory molecules such as CD80 or CD86 to CD28, CD40/CD40L; and (iii) accessory molecules such as cytokines.

Co-stimulation or the provision of two distinct signals to T-cells is a widely accepted model of lymphocyte activation of resting T lymphocytes by antigen-presenting cells (APCs) (Lafferty and Cunningham, 1975). This model further provides for the discrimination of self from non-self and immune tolerance (Bretscher and Cohn, 1970; Bretscher, 1999; Jenkins and Schwartz, 1987). The primary signal, or antigen specific signal, is transduced through the T-cell receptor (TCR) following recognition of foreign antigen peptide presented in the context of the major histocompatibility-complex (MHC). The second or co-stimulatory signal is delivered to T-cells by co-stimulatory molecules expressed on antigen-presenting cells (APCs), and induce T-cells to promote clonal expansion, cytokine secretion and effector function (Lenschow et al., 1996). In the absence of costimulation, T-cells can become refractory to antigen stimulation, do not mount an effective immune response, and further may result in exhaustion or tolerance to foreign antigens.

Immune checkpoint protein: PD-L1 and OX40 Immune checkpoints refer to a group of inhibitory and stimulatory pathways mostly initiated by ligand-receptor interaction hardwiring the immune system, specifically T-cell mediated immunity, to maintain self-tolerance and modulate the duration and amplitude of physiological responses in peripheral tissues in order to minimize collateral tissue damages normally (Pardoll, 2012).

Tumor cells co-opt certain checkpoint pathways as a major mechanism of immune resistance. For example, programmed cell death protein 1 ligand, PD-L1, is commonly up-regulated on tumor cell surface of human cancers.

The interaction of PD-L1 with its receptor, PD-1, expressed on tumor infiltrated lymphocytes (TILs), specifically on T cells, inhibits local T cell-mediated response to escape the immune surveillance (Liang et al., 2006; Sznol and Chen, 2013). Thus, the inhibition of immunosuppressive signals on cancer cells, or direct agonistic stimulation of T cells, results in and/or induces a strong sustained anti-tumor immune response. Recent clinical studies strongly suggested blockage of immune checkpoint proteins via antibody or modulated by soluble ligands or receptors are the most promising approaches to activating therapeutic antitumor immunity (Topalian et al., 2014). Currently, anti-PD-1 and anti-CTLA-4 (cytotoxic T-lymphocyte-associated antigen-4) antibodies have been approved by FDA to treat diseases such as melanomas.

Another co-stimulator molecule is the OX40 receptor (CD134), a member of the TNFR superfamily, which is membrane-bound and is expressed primarily on activated CD4+ T cells (Paterson et al., 1987). Signaling through the OX40 receptor (hereinafter "OX40") is costimulatory to effector T cells and causes proliferation of T-cells (Watts, 2005; Weinberg et al., 1994). Studies of OX40 suggest that its major role is to dictate the number of effector T-cells that accumulate in primary immune responses, and consequently to govern the number of memory T-cells that subsequently develop and survive (Croft, 2003).

A number in vitro studies have been shown that OX40 provides a costimulatory signal resulting, in enhanced T cell proliferation and cytokine production.

Bi-specific/bi-functional antibody The idea of using bispecific antibodies to efficiently retarget effector immune cells toward tumor cells emerged in the 1980s (Karpovsky et al., 1984; Perez et al., 1985; Staerz et al., 1985). Bispecific scaffolds are generally classified in two major groups with different pharmacokinetic properties, based on the absence or presence of an Fc fragment, IgG-like molecules and small recombinant bispecific formats, most of them deriving from single chain variable fragment (scFv). Through their compact size, antibody fragments usually penetrate tumors more efficiently than IgG-like molecules but this benefit is mitigated by a short serum half-life (few hours) limiting their overall tumor uptake and residence time (Goldenberg et al., 2007). By contrast, the presence of an Fc fragment, which binds to the neonatal Fc receptors, provides a long serum half-life (>10 days) to the IgG-like formats, favoring tumor uptake and retention, but limits tumor penetration.

Recent studies have highlighted the therapeutic efficacy of immunotherapy, a class of cancer treatments that utilize the patient’s own immune system to destroy cancerous cells. Within a tumor the presence of a family of negative regulatory molecules, collectively known as "checkpoint inhibitors," can inhibit T cell function to suppress anti-tumor immunity.

Checkpoint inhibitors, such as CTLA-4 and PD-1, attenuate T cell proliferation and cytokine production. Targeted blockade of CTLA-4 or PD-1 with antagonist monoclonal antibodies (mAbs) releases the "brakes" on T cells to boost anti-tumor immunity. Generating optimal "killer" CD8 T cell responses also requires T cell receptor activation plus co-stimulation, which can be provided through ligation of tumor necrosis factor receptor family members, including OX40 (CD134) and 4-1BB (CD137). OX40 is of particular interest as treatment with an activating (agonist) anti-OX40 mAb augments T cell differentiation and cytolytic function leading to enhanced anti-tumor immunity against a variety of tumors. When used as single agents, these drugs can induce potent clinical and immunologic responses in patients with metastatic disease (Linch et al., 2015). [011A] In this specification where reference has been made to patent specifications, other external documents, or other sources of information, this is generally for the purpose of providing a context for discussing the features of the invention. Unless specifically stated otherwise, reference to such external documents is not to be construed as an admission that such documents, or such sources of information, in any jurisdiction, are prior art, or form part of the common general knowledge in the art.

SUMMARY The present disclosure designed to investigate the bispecific antibody with immunomodulatory aiming for the treatment of patient with cancers, such as prostate cancer, lung cancer, NSCLC, melanoma, lymphoma, breast cancer, head and neck cancer, RCC, or ovarian cancer were examined.

The present disclosure provides an antibody or an antigen-binding portion thereof binding to OX40 (CD134), comprising: a heavy chain variable region comprising an amino acid sequence of at least about 80% sequence homology to the amino acid sequence selected from the group consisting of (followed by page 5a) SEQ ID NO. 6, SEQ ID NO. 8, amino acid 128-246 of SEQ ID NO. 10, and amino acid 124-241 SEQ ID NO. 13; and a light chain variable region comprising an amino acid sequence of at least about 80% homology to the amino acid sequence selected from the group consisting of amino acid 1-108 of SEQ ID NO. 5, 1-108 of SEQ ID NO. 7, 1-112 of SEQ ID NO. 10, and 1-108 of SEQ ID NO. 13. [0013A] In a particular aspect, the present invention provides an antibody or an antigen-binding portion thereof binding to OX40 (CD134), comprising: a heavy chain variable region comprising complementarity-determining regions (CDRs) CDR1, CDR2, and CDR3 set forth in the sequence of SEQ ID NO: 6 and a light chain variable region comprising CDR1, CDR2, and CDR3 set forth in amino acids 1-108 of SEQ ID NO: 5; a heavy chain variable region comprising CDR1, CDR2, and CDR3 set forth in the sequence of SEQ ID NO: 8 and a light chain variable region comprising CDR1, CDR2, and CDR3 set forth in amino acids 1-108 of SEQ ID NO: 7; a heavy chain variable region comprising CDR1, CDR2, and CDR3 set forth in amino acids 128-246 of SEQ ID NO: 10 and a light chain variable region comprising CDR1, CDR2, and CDR3 set forth in amino acids 1-112 of SEQ ID NO: 10; or a heavy chain variable region comprising CDR1, CDR2, and CDR3 set forth in amino acids 124-241 of SEQ ID NO: 13 and a light chain variable region comprising CDR1, CDR2, and CDR3 set forth in amino acids 1-108 of SEQ ID NO: 13. [0013B] In another particular aspect, the present invention provides an antibody or an antigen-binding portion thereof binding to PD-L1, comprising: a heavy chain variable domain comprising CDR1, CDR2, and CDR3 set forth in (followed by page 5b) the sequence of SEQ ID NO: 2 and a light chain variable region comprising CDR1, CDR2, and CDR3 set forth in amino acids 1-111 of SEQ ID NO: 1; or a heavy chain variable domain comprising CDR1, CDR2, and CDR3 set forth in the sequence of SEQ ID NO: 4 and a light chain variable region comprising CDR1, CDR2, and CDR3 set forth in amino acids 1-110 of SEQ ID NO: 3.

[FOLLOWED BY PAGE 6] In one embodiment, the antibody or the antigen-binding portion thereof is a single chain variable fragment (scFv) sequence selected from the group consisting of SEQ ID NOs. 10, 11, 12, and 13.

In one embodiment, the antibody or the antigen-binding portion thereof is a bispecific antibody.

In one embodiment, the bispecific antibody comprises an immune checkpoint protein binding site.

In one embodiment, the immune checkpoint protein binding site comprises a programmed cell death protein 1 ligand (PD-L1) binding site, PD-1 binding site, epidermal growth factor receptor (EGFR) binding site, human epidermal growth factor receptor 2 (HER2) binding site, cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) binding site, or lymphocyte activation gene 3 (LAG3) binding site.

The present disclosure also provides an antibody or an antigen-binding portion thereof binding to PD-L1, comprising: a heavy chain variable domain comprising an amino acid sequence of at least about 80% sequence homology to the amino acid sequence selected from the group consisting of SEQ ID NO. 2 and SEQ ID NO. 4; and a light chain variable domain comprising an amino acid sequence of at least about 80% homology to the amino acid sequence selected from the group consisting of amino acid 1-111 of SEQ ID NO. 1 and 1-110 of SEQ ID NO. 3.

The present disclosure also provides a bispecific antibody comprising at least one of polypeptide chain, wherein the polypeptide chain comprises an OX40 binding site and a PD-L1 binding site. The OX40 binding site comprises a heavy chain variable region comprising an amino acid sequence of at least about 80% sequence homology to the amino acid sequence selected from the group consisting of SEQ ID NO. 6, SEQ ID NO. 8, amino acid 128-246 of SEQ ID NO. 10, and amino acid 124-241 SEQ ID NO. 13; and a light chain variable region comprising an amino acid sequence of at least about 80% homology to the amino acid sequence selected from the group consisting of amino acid 1-108 of SEQ ID NO. 5, 1-108 of SEQ ID NO. 7, 1-112 of SEQ ID NO. 10 and 1-108 of SEQ ID NO. 13. The PD-L1 binding site comprises a heavy chain variable domain comprising an amino acid sequence of at least about 80% sequence homology to the amino acid sequence selected from the group consisting of SEQ ID NO. 2 and SEQ ID NO. 4; and a light chain variable domain comprising an amino acid sequence of at least about 80% homology to the amino acid sequence selected from the group consisting of amino acid 1-111 of SEQ ID NO. 1 and 1-110 of SEQ ID NO. 3.

In one embodiment, the polypeptide chain further comprises a Fc domain, a Fab fragment, and a scFv. The Fab fragment is connected to the N-terminus of the Fc domain, and the Fab fragment comprises the PD-L1 binding site.

The scFv is connected to the C-terminus of the Fc domain, and the scFv comprises the OX40 binding site.

In one embodiment, the polypeptide chain further comprises a linker between the Fc domain and the scFv.

In one embodiment, the scFv comprises an amino acid sequence selected from the group consisting of amino acid 455-707 of SEQ ID NO. 18, 455-708 of SEQ ID NO. 19, 455-701 of SEQ ID NO. 20, 455-706 of SEQ ID NO. 21, 455-706 of SEQ ID NO. 22, 455-706 of SEQ ID NO. 23, 455-706 of SEQ ID NO. 24, 455-706 of SEQ ID NO. 25, 455-706 of SEQ ID NO. 26, 455-706 of SEQ ID NO. 27, 455-706 of SEQ ID NO. 28, and 455-706 of SEQ ID NO. 29.

In one embodiment, the bispecific antibody comprises one pairs of polypeptide chains.

In one embodiment, the bispecific antibody is an IgG, IgE, IgM, IgD, IgA, or IgY antibody.

In one embodiment, the bispecific antibody is an IgG antibody.

In one embodiment, the IgG antibody is an IgG1, IgG2, IgG3, or IgG4 antibody.

The present disclosure also provides an antibody-drug conjugate comprising a therapeutic agent, and an antibody or an antigen-binding portion binding PD-L1 and/or OX40, wherein the therapeutic agent is covalently conjugated to the antibody or the antigen-binding portion by a linker.

In one embodiment, the antibody or an antigen-binding portion is selected from the above mentioned antibody or an antigen-binding portion.

The present disclosure also provides a pharmaceutical composition comprising the antibody, the antigen-binding portion thereof, or the bispecific antibody as above mentioned, and at least one pharmaceutically acceptable carrier.

The present disclosure also provides a method of treating cancer comprising administering to the subject in need thereof an effective amount of the antibody, the antigen-binding portion thereof, or the bispecific antibody as above mentioned.

In one embodiment, the cancer is selected from the group consisting of prostate cancer, lung cancer, Non-Small Cell Lung Cancer (NSCLC), melanoma, lymphoma, breast cancer, head and neck cancer, renal cell carcinoma (RCC), and ovarian cancer.

The present disclosure also provides a nucleic acid molecule encoding the antibody, the antigen-binding portion thereof, or the bispecific antibody as above mentioned.

It is to be understood that both the foregoing general description and the following detailed description are by examples, and are intended to provide further explanation of the invention as claimed. [0033A] In the description in this specification reference may be made to subject matter which is not within the scope of the appended claims. That subject matter should be readily identifiable by a person skilled in the art and may assist in putting into practice the invention as defined in the appended claims. [0033B] Unless the context clearly requires otherwise, throughout the description and the claims, the words ‘comprise’, ‘comprising’ and the like are to be construed in an inclusive sense as opposed to an exclusive or exhaustive sense; that is to say in the sense of "including but not limited to".

[FOLLOWED BY PAGE 9a] BRIEF DESCRIPTION OF THE DRAWINGS The invention can be more fully understood by reading the following detailed description of the embodiment, with reference made to the accompanying drawings as follows: Fig. 1 shows immune checkpoints modulating T-cell mediated immunity.

Antibody either agonistic or antagonistic against the checkpoints, such as anti-ICOS, anti-CD28, anti-OX40, and anti-CD27, or anti-PD-1, anti-CTLA4, anti-LAG3, anti-BTLA, could be used to construct the bi-functional fusion protein depending on applications.

[FOLLOWED BY PAGE 10] Figs. 2A and 2B show the screening of phage clone by direct ELISA for PD-L1 expressed HEK293 cells.

Figs. 3A and 3B show the screening of phage clone by cell-based ELISA with OX40 expressed HEK293 cells.

Fig. 4 shows purified antibody leads specific for PD-L1 by SDS-PAGE with non-reducing reagent to reveal the integrity and purity.

Fig. 5 shows purified antibody leads specific for OX40 by SDS-PAGE with non-reducing or reducing reagent to reveal the integrity and purity.

Fig. 6 shows examples of the direct ligand binding activity of purified anti-immune check point proteins and anti-PD-L1 antibody leads against PD-L1.

Ligand pre-coated wells were first incubated with various concentrations of antibody leads as indicated. The bound proteins were then detected with HRP conjugated goat anti-human IgG Fab specific antibody and OD readings were plotted.

Fig. 7 shows examples of the direct ligand binding activity of purified anti-immune check point proteins and anti-OX40 antibody leads against OX40.

Ligand pre-coated wells were first incubated with various concentrations of antibody leads as indicated. The bound proteins were then detected with HRP conjugated goat anti-human IgG Fab specific antibody and OD readings were plotted.

Fig. 8 shows the flow analysis using PD-L1expression 293 cells. PD-L1 expression HEK293 cells were first incubated with purified antibody leads, and the bound antibodies were detected with Alexa-488 conjugated goat anti-human IgG (H+L) followed by fluorescence-activated cell sorter (FACS) analysis.

Fig. 9 shows the flow analysis using OX40 expression 293 cells. OX40 expression HEK293 cells were first incubated with purified anti-OX40 antibody leads, and the bound antibodies were detected with Alexa-488 conjugated goat anti-human IgG (H+L) followed by FACS analysis. NS: no staining.

Fig. 10 shows the blockage of PD-1/PD-L1 interaction with purified anti-PD-L1 antibodies. Purified antibodies as indicated were applied with biotinylated-PD-L1-Fc and recombinant human PD-1/His (hPD-1/His) to evaluate the inhibition activity of PD-1/PD-L1 interaction. The binding recombinant PD-L1-Fc and hPD-1/His was detected by streptavidin-HRP and analysis by ELISA.

Figs. 11A and 11B show anti-PD-L1 antibody leads with 1 or 10 µg/mL stimulates T-cell proliferation and induces IL-2 and/or IFN-? production in a mixed lymphocyte reaction (MLR) assay after 3 days (Fig. 11A) or 5 days (Fig. 11B) antibody treatment.

Fig. 12A shows the ability of anti-OX40 antibody leads to enhance the CD3+ T cell activation with dosage response as well as reference antibody.

Fig. 12B shows the concentration of human IL-2 and IFN-? present in cell culture media following 3 days of stimulation of human T cells with plate bound anti-CD3 and several concentrations of anti-OX40 antibody leads.

Figs. 13A and 13B show the concentration of human IL-2 (Fig. 13A) and IFN-? (Fig. 13B) present in cell culture media following 3 days of stimulation of human T cells with plate bound anti-CD3 and several concentrations of OX40 specific antibody leads.

Fig. 14 shows the structure of an antibody heavy chain Fc fused with an OX40 specific scFv domain.

Fig. 15 shows examples of PAGE-gel analysis of anti-immune check point antibodies-human OX40 fusion proteins. Purified fusion proteins, anti-PD-L1-OX40 scFv fusion proteins were shown to have a molecular weight about 220 kDa (non-reducing), and heavy chain fusion has about 85 kDa and light chain is about about 25 kDa (reduced) in both antibody fusions.

Figs. 16A and 16B show bispecific antibody synergic stimulates T-cell activation for IL-2 and IFN-? production in a mixed lymphocyte reaction (MLR) assay after 3 days (Fig. 16A) or 5 days (Fig. 16B) with mono-, combined or anti-PD-L1-OX40 scFv bispecific antibody treatment.

Figs. 17A to 17E respectively show the aggregation and purity determination of Bi-specific antibodies, Anti-PD-L1-OX40 Ab and Anti-PD-L1-OX40 Ab-V1 to V4, with 5 different linkers in OX40 scFv.

Fig. 18 shows sequence variants among OX40 clone B17 scFv of Anti-PD-L1-OX40 Ab-V4 to V12 (SEQ ID NOS: 30-38).

Fig. 19 shows examples of PAGE-gel analysis of anti-immune check point antibodies-human OX40 fusion proteins. Purified fusion proteins, anti-PD-L1-OX40 Ab-V5 fusion proteins were shown to have a molecular weight about 220 kDa (non-reducing), and heavy chain fusion has about 80 kDa and light chain is about 30 kDa (reduced) in both antibody fusions.

Fig. 20 shows a flow chart illustrating the ELISA method for binding activity evaluation of bispecific antibody variants.

Fig. 21 shows the human PD-L1 binding activity of the bispecific antibody variants and its EC50.

Fig. 22 shows the human OX40 binding activity of the bispecific antibody variants and its EC50.

Fig. 23 shows the ex vivo serum stability of bispecific antibody variant, anti-PD-L1-OX40 Ab-V5.

Figs. 24A and 24B show the IL-2 production for 3 days (Fig. 24A) and IFN-? production for 5 days (Fig. 24B) after modulating T cell with mono-, combined or anti-PD-L1-OX40 Ab-V5 bispecific antibody treatment.

Fig. 25 is a graph showing the effect of anti-PD-L1-OX40 Ab-V5bispecific antibody treatment and monoclonal antibody treatment on the growth of PC-3 tumor in Fox Chase SCID Beige mice.

DETAILED DESCRIPTION Reference will now be made in detail to the present embodiments of the invention, examples of which are illustrated in the accompanying drawings.

Wherever possible, the same reference numbers are used in the drawings and the description to refer to the same or like parts.

The present invention describes the expression, purification and characterization of bi-functional proteins with isolated functional agonistic OX40 scFv fused to the C-terminus of Fc domain of anti-immune checkpoint protein antibodies. These proteins interact with its corresponding check point target shall transmit the inhibitory or stimulatory signal to modulate T-cell involved immunity. The components of Fc fusion proteins in present invention are of all human origins, and thus are expected to be non-immunogenic and can be used as therapeutics in human.

Bispecific molecules such as bispecific antibodies (BsAbs) provide a means of simultaneously targeting multiple epitopes on the same molecular target or different targets with a single therapeutic agent. As cancer therapeutics, they have the potential to confer novel or more potent activities, lower the cost of goods and facilitate the development of new therapeutic regimens in contrast to a mixture of two mAbs (Chames and Baty, 2009; Hollander, 2009; Thakur and Lum, 2010). Recently, catumaxomab, a trifunctional bispecific antibody targeting human epithelial cell adhesion molecule (EpCAM) and CD3 has shown a clear clinical benefit in patients with peritoneal carcinomatosis of epithelial cancers (Heiss et al., 2010), and a bispecific T-cell engaging (BiTE) antibody with dual specificity for CD19 and CD3 has also demonstrated encouraging clinical activity in patients with CD19 expressing hematological malignancies (Bargou et al., 2008). Despite strong interest in the development of bispecific molecules as cancer therapeutics, technical challenges in the production of stable and active bispecific molecules have in the past hindered the clinical evaluation of most bispecific formats.

Many engineered antibody formats, including an IgG-like bispecific antibody have compromised stability or solubility (Bargou et al., 2008; Demarest and Glaser, 2008; Lu et al., 2005). Furthermore, several strategies have been taken to increase the product quality and in vivo stability of bispecific molecules, including PEGylation, conjugation with human serum albumin and Fc engineering (Muller et al., 2007; Ridgway et al., 1996). Bispecific single chain antibodies of the general form described above have the advantage that the nucleotide sequence encoding the four V-domains, two linkers and one spacer can be incorporated into a suitable host expression organism under the control of a single promoter. This increases the flexibility with which these constructs can be designed as well as the degree of experimenter control during their production. In addition, the Fc of IgG is a very another attractive scaffold for designing novel therapeutics because it contains all antibody functions except the binding ability. Fc engineering is important for improving the effectiveness of the bispecific antibodies. Therefore, the IgG-based conformation is using in present invention for two independent target on immune cells or target cell in immunotherapy.

Targeting immune-check point proteins are promising approaches to activate antitumor immunity. Anti-check point proteins, such as PD-1, PD-L1, CTLA-4, LAG3, etc., are currently evaluated clinically (Fig. 1). Preliminary data with blockers of immune checkpoint proteins have been shown to be able to enhance antitumor immunity with the potential to produce durable clinical responses. However, despite the remarkable clinical efficacy of these agents in a number of malignancies, it has become clear that they are not sufficiently active for many patients. Numerous additional immunomodulatory pathways as well as inhibitory factors expressed or secreted by myeloid and stromal cells in the tumor microenvironment are potential targets for synergizing with immune checkpoint blockade. Therefore, combining anticancer or bispecific antibody therapies has been essential to achieve complete remission and cures for patients with cancer.

The present invention describes the construction, expression and characterization of anti-immune checkpoint protein antibody Fc fused with different immune checkpoint protein specific scFv protein. The C-terminally positioned OX40 scFv in fusion constructs shall allow expanding the power of fusion proteins beyond OX40 activation approach if the fusion counterpart is immune system potentiating agent, such as anti-EGFR, anti-HER2, or anti-CTLA-4 antibody, for example.

Antibody generation from OmniMab library For the generation of therapeutic antibodies against PD-L1 or OX40, selections with the OmniMab phagemid library were carried out. The phagemid library is generated by AP Biosciences Inc. (APBio Inc.) from a collection of over hundred health donors B cells. Phages for the 1st round of pannings were prepared by Hyperphage (?13?07?????, Progen, Heidelberg, Germany). Solid phase panning and cell panning against PD-L1 or OX40 were applied for PD-L1 or OX40 specific binder selection and isolation from OmniMab library. Solid phase panning was performed using recombinant human PD-L1-Fc or OX40-Fc (APBio Inc.) in the first round selection and then HEK293 cells expressed PD-L1 or OX40 were used for two and three round enrichment. After three rounds selection, the specific PD-L1 or OX40 binders were screened and isolated by direct ELISA or cell-based ELISA with corresponding recombinant protein (Figs. 2A, 2B, 3A, and 3B). Pre-coated PD-L1-Fc recombinant proteins or OX40 expressed 293 cells were blotted with supernatant containing rescued phages for 1 hour and washed with PBS containing 0.1 % Tween-20 for three times. Bound phages were detected by HRP conjugated anti-M13 antibody (Roche) and TMB substrate was used for signal development. The OD450 readings were recorded. The positive binders were isolated and sent for sequencing to confirm the sequence and diversity of heavy chain and light chain. The variable region of heavy chain and light chain specific to PD-L1 or OX40 were described from the SEQ ID NO. 1 to SEQ ID NO. 8: SEQ ID NO. 1 is the light chain of PD-L1 clone 6, SEQ ID NO. 2 is the variable region of heavy chain of PD-L1 clone 6, SEQ ID NO. 3 is the light chain of PD-L1 clone 32, SEQ ID NO. 4 is the variable region of heavy chain of PD-L1 clone 32, SEQ ID NO. 5 is the light chain of OX40 clone B17, SEQ ID NO. 6 is the variable region of heavy chain of OX40 clone B17, SEQ ID NO. 7 is the light chain of OX40 clone B19, SEQ ID NO. 8 is the variable region of heavy chain of OX40 clone B19. As shown in the Figs. 2A, 2B, 3A and 3B, several clones were isolated and known to be recognized specifically for corresponding antigen as comparing with negative control.

Subcloning and expression/purification of selected PD-L1 or OX40 specific binder as IgG format To facilitate the quick screening of specific binder with functionality in T cell activation, the heavy chains and light chains of positive binders against PD-L1 or OX40 by ELISA were then amplified, digested and sub-clone into APBio specialized IgG expression vector carrying IgG4 constant region (SEQ ID NO. 9). After sequence validation, the plasmids were then prepared and transfected into HEK293 cells for antibody expression with 293 fectin transfection reagent (Invitrogen). After 4 days culture, the antibody secreted into serum-free medium is affinity purified from culture supernatant by Protein G chromatography. Purified antibody is then concentrated, followed by dialysis in PBS buffer. The final concentration of dialyzed protein is determined by NanoDrop2000 spectrophotometer and the purity and integrity are determined by SDS-PAGE with or without reducing reagent as shown in the Figs. 4 and 5.

The integrity of various purified antibody leads, either PD-L1 specific or OX40 specific, is normal in the HEK293 cells as well as reference antibody, MPDL3280A for PD-L1 or GSK3174998 for OX40.

In one embodiment, the present disclosure provides an antibody or an antigen-binding portion thereof binding to OX40 (CD134), comprising a heavy chain variable region and a light chain variable region. The heavy chain variable region comprises an amino acid sequence of at least about 80% sequence homology to the amino acid sequence selected from the group consisting of SEQ ID NO. 6, SEQ ID NO. 8, amino acid 128-246 of SEQ ID NO. , and amino acid 124-241 SEQ ID NO. 13. In some examples, the heavy chain variable region comprises an amino acid sequence of at least about 85%, 90%, or 95% sequence homology to the amino acid sequence as above mentioned. The light chain variable region comprising an amino acid sequence of at least about 80% homology to the amino acid sequence selected from the group consisting of amino acid 1-108 of SEQ ID NO. 5, 1-108 of SEQ ID NO. 7, 1-112 of SEQ ID NO. 10, and 1-108 of SEQ ID NO. 13. In some examples, the light chain variable region comprises an amino acid sequence of at least about 85%, 90%, or 95% sequence homology to the amino acid sequence as above mentioned.

In one embodiment, the present disclosure provides an antibody or an antigen-binding portion thereof binding to PD-L1, comprising a heavy chain variable domain and a light chain variable domain. The heavy chain variable domain comprises an amino acid sequence of at least about 80% sequence homology to the amino acid sequence selected from the group consisting of SEQ ID NO. 2 and SEQ ID NO. 4. In some examples, the heavy chain variable region comprises an amino acid sequence of at least about 85%, 90%, or 95% sequence homology to the amino acid sequence as above mentioned.

The light chain variable domain comprises an amino acid sequence of at least about 80% homology to the amino acid sequence selected from the group consisting of amino acid 1-111 of SEQ ID NO. 1 and 1-110 of SEQ ID NO. 3.

In some examples, the light chain variable region comprises an amino acid sequence of at least about 85%, 90%, or 95% sequence homology to the amino acid sequence as above mentioned.

Binding activity determination for PD-L1, OX40 specific IgG leads by direct ELISA Purified antibody leads against PD-L1 or OX40 (anti-PD-L1 antibody leads or anti-OX40 antibody leads) were then applied for ELISA binding characterization on human PD-L1-Fc or OX40-Fc in a direct coated setup.

Figs. 6 and 7 showed the ELISA binding result for anti-PD-L1 and anti-OX40 antibodies, respectively. For PD-L1 specific antibodies, most leads showed a similar or better binding activity with reference antibody (Ref Ab, MPDL3280A, Roche).

Purified human PD-L1 or OX40 IgG1 Fc chimera (PD-L1-Fc or OX40-Fc, APBio) was dialyzed in Phosphate Buffered Saline (PBS), adjusted to 1mg/mL and then diluted with PBS to a final concentration of 1 µg/mL. Nunc-Immuno Maxisorp 96 well plates were coated with 0.1 mL per well of recombinant PD-L1-Fc or OX40-Fc chimera leaving empty wells for nonspecific binding controls and incubated at 4°C overnight. The PD-L1-Fc or OX40-Fc chimera solution was removed and the plates were washed three times with 0.4 mL wash buffer (0.1 % Tween-20 in PBS). 0.4 mL blocking buffer (5% low-fat milk powder in PBS) was added to all wells and incubated at room temperature for 1 hour with mixing. The blocking buffer was removed and plates washed three times with 0.4 mL wash buffer. Serial dilutions of the PD-L1 or OX40 test antibodies were prepared in PBS and 0.1 mL diluted Ab was added per well.

Plates were incubated 1 hour at room temperature. Antibody solution was removed and the plates washed three time with 0.4 mL wash buffer per well.

Horseradish peroxidase labeled goat anti-human IgG, F(ab’) specific F(ab’) antibody (Jackson Immunoresearch #109097) was diluted 1:2000 with PBS and added 0.1 mL per well. The plates were incubated 1 hour at room temperature and washed with 0.4 mL per well wash buffer. 0.1 mL TMB reagent (Invitrogen) was added and incubated for 1 to 5 minutes at room temperature. The reaction was stopped by adding 0.05 mL 1N HCl and absorbance was read at 450 nm on a Bio-Tek Spectra. Calculated EC50 for anti-PD-L1antibody leads to PD-L1 showed most leads possess good binding activity as well as MPDL3280A (Ref Ab) by direct ELISA (Fig. 6). On the contrary, most anti-OX40 antibody leads showed much lower binding activity as comparing with reference antibody (Ref Ab, GSK3174998)(Fig. 7).

Binding activity determination for PD-L1 and OX40 specific IgG leads by FACS Purified antibody leads (anti-PD-L1 antibody leads or anti-OX40 antibody leads) were also applied for flow cytometry to determine and compare the binding activity with PD-L1 or OX40 expressed HEK293 cells. Figs. 8 and 9 show the binding activity of corresponding antibody leads as indicated by FACS with stable expressed PD-L1 or OX40 HEK293 cells.

FACS analysis of PD-L1 stable expression 293 cells stained with anti-PD-L1 antibody leads to examine the PD-L1 binding activity, stable expression cells were incubated with 1 µg/mL purified anti-PD-L1 antibody leads, reference antibody (Ref Ab MPDL3280A) or with isotype antibody as negative control on ice for 1 hr. The cells were washed three times with 1x PBS and then incubated with Alexaconjugated goat anti-human IgG (H+L) (Invitrogen Inc.) on ice for additional 1 hr. After staining, the cells were washed three times with 1x PBS, resuspended in 1x PBS/2%FBS before analyzed by FACS Calibur (BD Biosciences, Inc.) and FlowJo (TreeStar, LLC). Same scenario, the binding activity of anti-OX40 antibody leads for stable expressed OX40 HEK293 cells in Fig. 9 were also executed with a similar strategy and analyzed as described above. As shown in the Fig. 8, most anti-PD-L1 antibody leads possess a good binding activity as well as reference antibody.

This indicated the phage clones selected from the OmniMab library indeed recognize the native PD-L1 in the cells.

This phenomenon is also observed for anti-OX40 antibody leads as shown in the Fig. 9. FACS analysis of OX40 stable expression 293 cells clone 2D5 stained with purified anti-OX40 antibodies leads to examine the OX40 binding activity, stable expression cells were incubated with 2 µg/mL anti-OX40 reference Abs (OX40 ref.) or anti-CD137 reference Abs (CD137 ref.) as control antibody on ice for 1hr. The cells were washed three times with 1x PBS and then incubated with Alexaconjugated goat anti-human IgG (H+L) (Invitrogen Inc.) on ice for additional 1hr. After staining, the cells were washed three times with 1x PBS, resuspended in 1x PBS/2%FBS before analyzed by FACS Calibur (BD Biosciences, Inc.) and FlowJo (TreeStar, LLC).

Ligand competition binding (ELISA Assay) Antibody leads were showed the binding selectivity and affinity assay used to evaluate the anti-PD-L1 antibody leads of present invention for their ability to block binding of PD-L1 to PD-1.

Antibodies were tested for their ability to block the binding of the human PD-L1-Fc chimera (PD-L1-Fc) to recombinant human PD-1/His (hPD-1/His) by ELISA. Purified recombinant hPD-1/His (APBio) was dialyzed to 1 mg/mL in PBS and then conjugated with biotin (Abcam). Nunc Maxisorp 96 well pate was coated with 250 ng hPD-1/His per well in PBS overnight. The hPD-1/His solution was removed and the plates were washed three times with 0.4 mL wash buffer (0.1 % Tween-20 in PBS). 0.4 mL blocking buffer (5% low-fat milk powder in PBS) was added to all wells and incubated at room temperature for 1 hour with mixing. During the blocking step the antibody stocks were diluted in a range from 200 nM to 0 nM in PBS with 2 folds serial dilution. Purified recombinant biotinylated-PD-L1-Fc chimera was diluted to 4 µg/mL in PBS.

The PD-1/His coated plates were washed three times with 0.2 mL wash buffer (0.1 % Tween 20 in PBS). 60 µL antibody dilutions (anti-PD-L1 antibody leads or Ref Ab MPDL3280A) were added alone with 60 µL biotinylated-PD-L1-Fc chimera and incubated at room temperature for 1 hour. Plates were washed as described previously. Streptavidin-HRP was diluted 1:2000 in PBS, 100 µL of the resulting solution added to the wells of the washed plated, and incubated at room temperature for 1 hour. Plates were washed as previously described, 100 µL TMB substrate solution was added to each well and incubated for 10 minutes. The reaction was stopped with 50 µL 1N HCl and absorbance at 450 nm read using Bio-Tek reader and showed in Fig. 10. Partial antibody leads are showed to inhibit the interaction between PD-PD-L1 by competition ELISA.

Most antibody leads revealed a similar blocking activity as comparing with reference antibody (Ref Ab MPDL3280A).

Enhanced stimulation of T cell activation by inhibition of PD-1:PD-L1 ligand interaction for anti-PD-L1 antibody The PD-1 signaling pathway inhibits moderate TCR/CD28 costimulatory signals, with cytokine production being reduced first without a decrease in T cell proliferation. As the TCR/CD28 costimulatory signals weaken, the PD-1 pathway dominates, with a great reduction in cytokine production accompanied by a reduction in proliferation. Accordingly in order to confirm that the inhibition of the PD-1 via inhibition of the interaction with PD-L1, human antibodies of the invention enhances T cell activation, mixed lymphocyte reactions (MLRs) are performed.

Monocytes from human whole blood were enriched by RosetteSep™ Human Monocyte Enrichment Cocktail (Cat. No.15068) and cultured in differentiation medium, RPMI 1640 with 10%FBS, 100 ng/mL (1000 U/mL) GM-CSF, 100 ng/mL (500 U/mL) for 6 days. The differentiate dendritic cells (DC) from monocyte were checked by DC-SIGN-PE, anti-CD14 conjugated with FITC Ab, anti-CD83 conjugated with PE Ab, or anti-CD80 conjugated with FITC Ab to validate the differentiation and used to be APCs in MLRs.

Allogenic CD4+ T cells from human whole blood were isolated by RosetteSep™ Human CD4 T Cell Enrichment Cocktail (Cat. NO. 15062).

The purity of CD4+ T cells were checked with anti-CD4 conjugated APC Ab to make sure the purity is above 95% and then labeled with 1uM CFSE (CellTrace CFSE cell proliferation kit, Life technologies, Cat. NO. C34554) for T cells proliferation assay. Labeled CD4+ T cells were used to co-culture with immature DC with different antibody leads as indicated for 3 and 5 days to see whether the antibody leads could restore the T cell activation through blocking the interaction between PD-1 and PD-L1. After 3 and 5 days incubation, the supernatant were collected for cytokine, such as IL-2 and IFN-? quantitation by ELISA. The addition of anti-PD-L1 antibody leads (clones 6, 32, 28, 51, 64, 27, and 37) to cultures of immature dendritic cells plus allogeneic T cells is predicted to result in an increase in T cell proliferation and cytokine production, as compared to isotype IgG (iso#1, #2) treated cultures and showed in the Figs. 11A and 11B. The IL-2 and IFN-? production increase significantly in the MLRs as comparing with isotype antibody treatment after 3 days (Fig. 11A) or 5 days (Fig. 11B) antibody treatment, especially for anti-PD-L1 antibody clone 6. The cytokine increment is still obviously after 5 days antibody treatment and similar to reference antibody (ref), MPDL3280A. This indicated the anti-PD-L1 antibody clone 6 should be one of the potential leads for bispecific antibody composite.

Agonistic activity assay of anti-OX40 antibody In order to activate OX40 costimulation of T-cell proliferation and cytokine production, the purified antibody leads were functionally screened for their ability to enhance cytokine production, proliferation, and to induce proliferation in human CD3+ T-cells. The anti-CD3 antibody (OKT3, BioLegend Cat. No.317304) and anti-OX40 antibody leads (clones B6, B70, B120, A4, B17, B19, and B30), reference antibody (GSK3174998) or isotype antibodies (iso#1, #2) were coated in the Maxisorp 96-well plate. Meanwhile, naïve human CD3+T-cells were isolated from the human blood from heathy adult volunteers using a commercially available RosetteSep™ Human T Cell Enrichment Cocktail (STEMCELL Cat. No.15061) as manufacture’s described.

The isolated CD3+ T cells were then labeled by CFSE (CellTrace CFSE cell proliferation kit, Life technologies, Cat. NO. C34554) and seeded as 1 X 10 cells/mL into the antibody pre-coated well containing RPMI 1640 medium, 10% fetal bovine serum and 2.5 mM L-glutamine to determine the cell proliferation and cytokine production. After 3 days culture, the cells were collected for proliferation assay by flow cytometry and medium were then analyzed for IL-2 and IFN-? production by quantitation ELISA.

The screening of anti-OX40 antibody leads with agonistic activity in T cell activation was showed in the Fig. 12A. All anti-OX40 antibody leads showed the ability to enhance the CD3+ T cell activation with dosage response as well as reference antibody. Higher dosage antibody treatment showed obviously higher T cell activation activity. Meanwhile, cytokine production (Fig. 12B), such as IL-2 and IFN-? also revealed similar T cell activation response, especially for anti-OX40 antibody lead clone B17. Cytokine is highly induction after anti-OX40 antibody lead B17 3 days treatment. The enhancement is much higher than reference antibody treatment, this implicated clone B17 should be one of the candidates for bispecific antibody construction.

As the data shown in the Figs. 13A and 13B, both anti-OX40 antibody leads, clones B17 and B19, were showed a better agonistic activity in the assay after anti-OX40 antibody leads (B17 or B19) 3 days treatment. Either IL-2 production or IFN-? production shows an obvious enhancement upon antibody treatment and revealed does-dependent correlation. Higher cytokine productions were recorded in higher dose antibody treatment.

In order to evaluate the agonistic activity of OX40 antibody leads, B17 and B19, the EC50 were also determined as well as agonistic activity assay and cytokine production were recorded for comparison.

Construction, Expression and Purification of Anti-PD-L1-OX40 scFv antibody Since the bispecific is designed as IgG based fused with scFv format, the structure of anti-immune checkpoint antibody Fc-terminally fused with OX40 scFv. Antibody can be inhibitory anti-immune checkpoint antibodies, such as anti-PD-L1, anti-PD-1, anti-CTLA4, anti-LAG3, etc., or stimulatory antibodies, such as anti-CD28, anti-CD137, anti-CD27, anti-ICOS, etc. A linker is placed between antibody Fc and OX40 scFv to generate the bispecific antibody as depicted in Fig. 14.

In some embodiment, the anti-PD-L1 antibody lead clone 6 is assigned to be IgG form, on the other hand, the anti-OX40 antibody lead would be transformed as scFv format to fuse at C-terminus of Fc region in anti-PD-L1 antibody lead clone 6. The transformation from antibody to scFv format could result in the reduction of the binding activity or specificity; therefore several anti-OX40 antibody leads were used to scFv transformation. Construction of bi-functional anti-PD-L1 antibody Fc fused with full-length OX40 scFv (SEQ ID NO. 10 as clone A4, SEQ ID NO. 11 as clone B17, SEQ ID NO. 12 as clone B19, or SEQ ID NO. 13 as clone B120). A short flexible peptide linker, (GGGGS) (SEQ ID NO. 14) was placed between, for example, anti-PD-L1 antibody heavy chain C-terminus of Fc region and N-terminal module of OX40 scFv to ensure correct folding and minimize steric hindrance. The coding sequences of anti-PD-L1-OX40 scFv antibodies were shown in SEQ ID NO. 16 (anti-PD-L1-clone 6 heavy chain-OX40 clone B17 scFv) and NO. 17 (anti-PD-L1-clone 6 heavy chain-OX40 clone B19 scFv). The constructed antibody Fc fusion proteins were leaded by a signal peptide (SEQ ID NO. 15) and expressed by mammalian cells, and purified from the transfected cell culture supernatant via 1-step Protein G chromatography. As shown in Fig. 15, greater than 90% purity can be obtained in a single step purification process and shows that purified fusion proteins have correct molecular weight (Mw = 220kD).

Enhanced stimulation of T cell activation for anti-PD-L1-OX40 scFv bispecific antibody leads in MLRs To determine the synergic cooperation of bispecific antibody in enhancing T cells activation through inhibition the interaction between PD-1 and PD-L1 and agonistic activation of OX40 signaling, the bispecific antibody leads, anti-PD-L1-OX40 scFv, were applied into MLRs as described above. IL-2 and IFN-? production were then recorded after 3 or 5 days antibody treatment.

Mono-, combination or bispecific antibody was applied as equal amount or equal mole to compare the synergic effect in T cell activation enhancement and isotype IgG was used a negative control. As the data showed in the Figs. 16A and 16B, the anti-PD-L1 antibody leads alone showed a significant IL-2 induction after 3 days treatment as well as reference antibody, MPDL3280A, on the contrary, the anti-OX40 antibody leads is unable to increase obviously upregulation of cytokine production, either after 3 days or 5 days antibody treatment. This is consisted with reference antibody, GSK3174998.

However, combination of the anti-OX40 antibodies and anti-PD-L1 antibodies showed a significant upregulation of cytokine production after 3 and 5 days antibody treatment. The synergic effect is also observed in the bispecific antibody leads treatment and increment of cytokine production is similar as well as combination treatment. This indicated the anti-PD-L1-OX40 scFv bispecific antibody leads also function as well as antibody combination treatment without loss any binding activities in the scFv transformation.

Aggregation and purity determination of Bi-specific antibody Since purified anti-PD-L1-clone 6-OX40 clone B17 scFv Ab revealed a lower purity (74.07%) by SEC-HPLC analysis after a single column protein A chromatography purification, therefore, several antibody variants were generated to improve the purity and reduce the aggregation for the bispecific antibody in the present invention. The linkers described as above were used to replace the linker in OX40 B17 scFv in the bispecific antibody, anti-PD-L1-OX40 Ab (SEQ ID NO. 16), and produced as anti-PD-L1-OX40 Ab-V1 to V4 (SEQ ID NO. 18 to SEQ ID NO. 21) in the CHO cells. Those variants were then purified and analyzed by XBridge Protein BEH SEC-HPLC column (Waters, Cat. No.186007640). The data was summarized as below Table 1, one of the bispecific antibody variants, anti-PD-L1-OX40 Ab-V4 revealed a significant improvement of antibody purity. The purity is enhanced from 74.07 to 92.27%. Therefore, the anti-PD-L1-OX40 Ab-V4 was used to engineer further to improve the antibody purity.

Table 1 Different linkers in OX40 B17 scFv Abbreviation Heavy chain/light Linker in OX40 B17 scFv Reference chain Anti-PD-L1-OX40 Anti-PD-L1OX40 GGGGSGGGGSGGGGS Int. J. Mol. Sci.

Ab B17 scFv-L1 HC/ (SEQ ID NO: 39) 2014, 15(12), Anti-PD-L1 6 LC 23658-23671 Anti-PD-L1-OX40 Anti-PD-L1OX40 SSGGGGSGGGGGGSS None Ab-V1 B17 scFv-L2 HC/ RSSL (SEQ ID NO: 40) Anti-PD-L1 6 LC Anti-PD-L1-OX40 Anti-PD-L1OX40 GGKGSGGKGTGGKGS Virol J. 2008; Ab-V2 B17 scFv-L3 HC/ GGKGS (SEQ ID NO: 5:21 Anti-PD-L1 6 LC 41) Anti-PD-L1-OX40 Anti-PD-L1OX40 GSASAPTLFPLVS DOI: Ab-V3 B17 scFv-L4 HC/ (SEQ ID NO: 42) 10.3892/mmr.

Anti-PD-L1 6 LC 2013.1502 Anti-PD-L1-OX40 Anti-PD-L1OX40 GSTSGSGKPGSGEGS PMID: 8309948 Ab-V4 B17 scFv-L5 HC/ TKG (SEQ ID NO: 43) Anti-PD-L1 6 LC For characterization the size distribution of bi-specific antibodies, samples were loaded onto XBridge Protein BEH SEC-HPLC column (Waters , Cat. No.186007640) using a Waters Alliance 2695 Separations Module.

Protein peak were detected at 280 nm using a Water 2996 PDA Detector. The mobile phase was isocratic 25 mM sodium phosphate (Sigma, Cat. No.04272 and Cat. No.04269) with 200 mM NaCl (AMRESCO, Cat. No.0241), pH 6.8, at a flow rate of 0.4 mL/min. Peak percentages were determined by the portions of peak area as shown in Figs. 17A to 17E.

Anti-PD-L1-OX40 Ab-V4 revealed a significant purity improvement (Fig. 17E). The bispecific antibody was engineered further in the OX40 B17 scFv fragment to improve purity again. Several residues in the OX40 B17 scFv showed in Fig. 18 were substituted with difference amino acid and heavy chain variants were pairing with anti-PD-L1 clone 6 light chain to generate several bispecific antibody variants, from anti-PD-L1-OX40 Ab-V5 to V12 (SEQ ID NO. 22 to SEQ ID NO. 29), and then expressed and purified as mentioned above.

The purity of bispecific antibody variants were summarized as below Table 2, the anti-PD-L1-OX40 scFv-V5 revealed the best purity in those antibody variants. The purity is aroused up to 96.46%. This is showed a superior purity for the engineered bispecific antibody and also revealed a good development ability for this bispecific antibody in the future. As shown in Fig. 19, the integrity of anti-PD-L1-OX40 Ab-V5 was also analyzed by SDS-PAGE and showed a good integrity under reducing and non-reducing condition.

Table 2 Purity of Antibody Antibody Purity by SEC-HPLC (%) Anti-PD-L1-OX40 Ab-V4 92.27 Anti-PD-L1-OX40 Ab-V5 96.46 Anti-PD-L1-OX40 Ab-V6 86.36 Anti-PD-L1-OX40 Ab-V7 88.04 Anti-PD-L1-OX40 Ab-V8 90.00 Anti-PD-L1-OX40 Ab-V9 87.89 Anti-PD-L1-OX40 Ab-V10 86.56 Anti-PD-L1-OX40 Ab-V11 86.61 Anti-PD-L1-OX40 Ab-V12 84.78 Meanwhile, the engineered bispecific antibody variants were also applied for binding activity evaluation for human PD-L1 and OX40 by direct ELISA as shown in Fig. 20. All bispecific antibody variants as indicated showed the same binding activity for human PD-L1 (Fig. 21), this binding activity is similar with anti-PD-L1 6 antibody. This phenomenon was also observed in the human OX40 binding assay (Fig. 22). Only anti-PD-L1-OX40 Ab-V10 showed a weaker binding activity for human OX40 as comparing with other variants. It indicated the engineering of OX40 scFv is not affected the OX40 binding activity. The binding activity is retained either for PD-L1 or OX40. Since the anti-PD-L1-OX40 Ab-V5 revealed a superior antibody purity and binding activity for PD-L1 and OX40, so the anti-PD-L1-OX40 Ab-V5 was chosen for serum stability.

Ex vivo serum stability The stability was assessed in human serum (BioreclamationIVT, Cat.

No.HMSRM) as well as serum from relevant preclinical species: rhesus monkey (BioreclamationIVT, Cat. No.RHSSRM), and CD1 mouse (BioreclamationIVT, Cat. No.MSESRM). Samples were added into different species serum for a final concentration of 15 µg/mL and incubated at 37°C water bath. Serum samples were collected after incubation times of 0, 1, 2, 3, 7, 10 and 14 day and stored frozen at -80°C until analysis.

Quantitation sandwich ELISA OX40-Fc was coated into ELISA plate (NUNC, Cat. No.442404) with 100 µL at 1 µg/mL in PBS and incubated for overnight at 4°C. Wash buffer was prepared as PBS with 0.1% Tween-20 (Sigma, Cat. No.P2287-500mL) and blocking buffer was prepared as 1% BSA (UniRegion, Cat.

No.UR-BSA001-100G) in wash buffer. Serum samples were prepared with -fold dilution with 3x serial dilution in blocking buffer and the standards were prepared at 10 nM with 3x serial dilution in blocking buffer. Biotinylated PD-L1-Fc was labeled with Biotin Fast conjugation Kit (abcam, Cat.

No.ab201796) using standard protocol and prepared at 30 nM in blocking buffer. Streptavidin-HRP (abcam, Cat. No.ab7403) was prepared at 1 µg/mL in blocking buffer. All the samples were added into each well for 100 µL after plates washed 3 times with wash buffer and incubated for 1 hour at ambient temperature. TMB development with 100 µL TMB solution (Invitrogen, Cat.

No.00-2023) for 2 min and stopped with 100 µL 1N HCl solution (Merck, Cat.

No.1.00317.1000). O.D. 450 nm absorption was read by ELISA reader (Biotek, Powerwave XS).

Anti-PD-L1-OX40 Ab-V5 was chosen for ex vivo serum stability because of its superior purity and binding activity for PD-L1 and OX40. The purified bispecific antibodies were mixed with serum from different species, such as human, mouse or monkey. After several days culture, the samples were took and analyzed by sandwich ELISA to determine the antibody amount. As shown in Fig. 23, the anti-PD-L1-OX40 Ab-V5 still showed a good serum stability after 14 days culture at 37°C. The concentration of the antibody is still above 70% either in human, mouse or monkey. It is indicated the antibody also have a good serum stability.

To measure the ability of the anti-PD-L1-OX40 Ab-V5 to modulate T cell responsiveness purified T cells will be cultured with allogeneic dendritic cells, prepared by culturing monocytes in GM-CSF and IL-4 for few days. Parallel plates were set up to allow collection of supernatants at day 3 and day 5 to measure IL-2 and IFN-? respectively using a commercial ELISA kit. As the data showed in Fig. 24A and 24B, the IL-2 and IFN-? production are highly upregulated in the bispecific antibody treatment (V5) as well as combination treatment after 3 or 5 days antibody treatment. Also, the enhancement is obviously superior than the anti-PD-L1 Ab or anti-OX40 Ab treatment alone.

This implicated the engineered bispecific antibody, V5, still possess the agonistic activity as well as combination treatment without functionality lost and could be developed as a therapeutic antibody for various solid tumor or cancer in the future.

Anti-tumor activity of bispecific antibody (In vivo model) The lack of rodent cross reactivity of the PD-L1 and OX40 in bispecific antibodies prevented the use of standard murine syngeneic or human xenograft tumor models for the assessment of anti-human tumor efficacy of the antibodies. Accordingly, a novel huPBL-SCID-Bg xenogeneic tumor mouse model was generated using a SCID-Bg mouse (CB.17/Icr.Cg scid bg Pkrdc Lyst /CrI), which harbors the beige (Bg) mutation lack murine T and B lymphocytes and functional NK cells. The anti-human tumor efficacy of the bispecific antibodies was assessed using this model as described below.

The PC-3 human prostate was obtained from American Type Culture Collection and was cultured in RPMI-1640 (Invitrogen) with L-glutamine, sodium pyruvate, penicillin/streptomycin, and 10% heat inactivated fetal bovine serum (FBS, Gibco Cat. NO. 10437). Cells were grown to confluency in T-150 Falcon flasks. Subsequently, cells were trypsinized (Trypsin 0.25%-EDTA; Invitrogen) and growth was scaled up to sufficient cell number for inoculation. Peripheral blood lymphocytes (PBMCs) were isolated from heparinized blood using Lymphoprep™ in accordance with the manufactures’ protocol (STEMCELL Technologies Inc.). Counted cell suspensions were combine such that each mouse received an injection of 0.75 x 10 PBMCs and 3 x 10 tumor cells in a single bolus injection of 0.1 mL in PBS. In order to facilitate the tumor cells grown in the mouse, another 0.1 mL matrigel was then mixed with the combined cell suspension and then immediately injected into prepare mice.

For each mouse, 0.2 mL volume of the combined cell suspension was injected subcutaneously into the right flank of the animal. After 14 days inoculation, the solid tumor is formed and reached around 250 to 300 mm and the bispecific antibody (3 mg/kg of Anti-PD-L1-OX40 Ab-V5), PD-L1 reference antibody (Ref Ab, MPDL3280A) or control antibody (Isotype) is challenged twice per week for three weeks with intraperitoneal injection (i.p.). Tumor measurement was made via Pressier caliper twice per week as well as test sample administration for the duration of the experiments and body weights were also recorded. Tumor volume was calculated using the following calculation: length X width X 0.44= volume (mm ) and plotted in the Fig. 25.

Mice were removed from the study in the event that the tumor volume reached 2000 mm or animal lost 20% of body weight before termination of the experiment. Similar results were observed when tumors were measured on day 7 post inoculation, and the animals were randomized according to tumor volume. For animal study, each group contained 6 mice. As the data showed in the Fig. 25, the bispecific antibody showed a significant anti-tumor efficiency in PC-3 xenografted mouse model. The tumor size is shirked at 18 days post tumor inoculation as well as PD-L1 reference antibody and continued to reduce below 100 mm . The PC-3 xenografted mouse model is preliminary demonstrated the anti-tumor of bispecific antibody and revealed its potential to be a therapeutic drug lead in the future.

Collectively, these results indicated bi-specific antibody sustain its immune checkpoint blocking in PD-1/PD-L1 signaling and agonistic activity for OX40 signaling. Studies are ongoing to further investigate the biological activity of these proteins using proper animal model, such as PC-3 tumor in humanized scid tmIwjI NOD.Cg-Prkdc Il2rg /SzJ (NSG) model.

The Fc region in the present invention could be from any immunoglobulin isotypes, subclasses, allotypes, or engineered mutants, such as knob and hole Fc fragment(s).

EXAMPLES The example below describe the generation of monoclonal antibodies suitable for therapeutic purpose targeting human PD-L1 and OX40.

Composite, human anti- human PD-L1 and anti-OX40 antibodies were generated from anti-PD-L1 antibody clone 6 and anti-OX40 antibody clone B17, respectively. Segments of human V region sequence were sourced from unrelated human antibody (germline and non-germline) sequence databases.

Example 1 Generation of IgG antibodies that bind to PD-L1 and Certain antibodies provided by present invention were originally generated from Fabs bind to human PD-L1 or OX40. The Fabs were selected from a phage display library, the OmniMab phagemid library, following alternating panning on corresponding Fc fusion proteins (PD-L1-Fc or OX40-Fc) and cells expressing human corresponding protein (PD-L1 or OX40). After direct ELISA or cell-based ELISA screening, the positive clones were then sequenced for heavy chain and light chain. These Fabs included those that are designated as "OM-PD-L1-6", and "OM-PDL1-32" etc. for PD-L1; "OM-OX40-A4", "OM-OX40-B17", and "OM-OX40-B19" etc. for OX40. PD-L1 antibodies PD-L1-Clone 3, PD-L1-Clone 6, and PD-L1-Clone 32 disclosed in this application were generated from "OM-PD-L1-6" and "OM-PDL1-32".

Meanwhile, OX40 antibodies OX40-A4, OX40-B17, and OX40-B19 disclosed in this application were generated from "OM-OX40-A4", "OM-OX40-B17", and "OM-OX40-B19" in HEK293 cell or CHO-S cells. And bispecific antibody targeting PD-L1 and OX40 simultaneously was designed as anti-PD-L1 6-OX40 scFv B17 antibody and anti-PD-L1 6-OX40 scFv B19 antibody. The amino acid sequence of the light chain variable region and heavy chain variable region of a given Fab are identical to the amino acid sequence of the light chain variable region and heavy chain variable region, respectively.

Example 2 In vitro binding of anti-PD-L1-OX40 scFv to its corresponding target Anti-PD-L1-OX40 bispecific antibody was constructed as shown in the Fig. 14 and expressed in the HEK293 cells or CHO-S cell. The medium containing bispecific antibody was affinity purified from culture supernatant by Protein G chromatography. Purified antibody is then concentrated, followed by dialysis in PBS buffer and analyzed by SDS-PAGE as shown in the Fig 15. To test direct binding of purified fusion proteins to PD-L1 or OX40 on ELISA, 100 ng/well recombinant PD-L1 or OX40 was coated in a 96-well ELISA plate.

Various concentrations of purified anti-PD-L1-OX40 scFv were then added to each well and incubated for 1 hr. After washing, 1:5000 dilution of anti-Fab HRP conjugate (Jackson Immunochemicals) was added to each well and incubated for another hour. After final washing, TMB substrate (Invitrogen Inc.) was added and OD absorbance at 450 nm was measured. The data analyzed by sigmoidal curve fitting using GraphPad Prism 5 and EC50 is calculated.

Example 3 Antigen binding specificity of anti-PD-L1-OX40 scFv by FACS analysis To test anti-PD-L1-OX40 scFv antibody binding specificity, stable PD-L1 expression 293 cells, IFN-? stimulated A549 or WiDr were stained with 1 µg/mL anti-PD-L1-OX40 scFv antibody for 1 hr on ice before wash three times with 1x PBS. The bound antibody fusion proteins were detected with Alexa-488 conjugated goat anti-human IgG (H+L) followed by FACS analysis. Isotype antibody was used as negative control for the test. Results showed anti-PD-L1-OX40 scFv sustains its antigen binding specificity as compared with anti-PD-L1 alone. The binding specificity of anti-PD-L1-OX40 scFv antibody was also tested using stable OX40 expression 293 cells.

Example 4 In vitro immunomodulatory effect of bi-functional proteins To measure the ability of the anti-PD-L1-OX40 scFv antibodies to modulate T cell responsiveness purified T cells will be cultured with allogeneic dendritic cells, prepared by culturing monocytes in GM-CSF and IL-4 for few days. Parallel plates were set up to allow collection of supernatants at day 3 and day 5 to measure IL-2 and IFN-? respectively using a commercial ELISA kit. Genentech/Roche’s humanized anti-PD-L1, MPDL3280A will be produced in-house and used as positive control. As the data showed in the Figs. 16A and 16B, the IL-2 and IFN-? production are highly upregulated in the bispecific antibody treatment as well as combination treatment after 3 or 5 days antibody treatment. Especially, the bispecific antibody composited by anti-PD-L1 antibody clone 6 and anti-OX40 antibody clone B17 (anti-PD-L1-OX40 scFv B17 Ab) or combination (anti-PD-L1 clone 6 Ab plus anti-OX40 clone B17 Ab) showed the enhancement of T cells activation is higher than the combination of PD-L1 and OX40 reference (PD-L1 Ref Ab plus OX40 Ref Ab). This indicated the anti-OX40 B17 antibody may possess a special epitope binding to result in a better agonistic activity as comparing with reference OX40 antibody, GSK3174998.

Example 5 Human leukocyte expansion induced by bispecific antibodies in vivo The lack of detectable cross-reactivity of the PD-L1 or OX40 antibodies with murine PD-L1 or OX40 and the requirement for the presence of human immune cells required the development of models for the in vivo functional assessment of the bispecific antibodies. Mice with the NOD genetic background carrying the severe combined immunodeficient (SCID) mutation and deficiency in the IL-2 receptor common gamma chain (commonly termed NSG) are able to support the engraftment of large number of human peripheral blood leukocytes (huPBL) and maintain engraftment for at least 30 days (King et al., 2008). This mouse model, also known as huPBL-NSG model, was used to assess the functional effect of in vivo systemic administration of the antibodies on human immune cells.

Specifically, 6 million freshly isolated human PBMCs were adoptively transferred via intravenous injection into huPBL-NSG mice. Nine days post PBMC injections, the animals were administered a single 1 mg/kg dose of mono-antibody, bispecific antibody or IgG4 isotype control antibody via intraperitoneal injection. At day 24 to 28 post PBMC engraftment, PBMC were stained with antibodies to human and murine CD45 assessed via flow cytometry. Forward and side scatter profiles were used to determine a lymphocyte gate. Bispecific antibodies were able to enhance expansion of human leukocytes as evidenced by increased proportion of human CD45+ cells in the peripheral blood of engrafted mice. For each group, n?6 mice.

Example 6 Inhibition of PC-3 or A498 tumor cell growth in huPBL-NSG by anti-PD-L1-OX40 scFv antibody PD-L1 positive human prostate cancer cell line, PC-3 (ATCC CRL-1435) or kidney cancer cell line, A498 (ATCC HTB-44™) can be used to establish xenograft models in huPBL-NSG mice. For tumor formation, 3 x 10 PC-3 cells (or A498 cells) /mouse will be injected subcutaneously in huPBL-NSG mice as described above. In order to assess the inhibitory effects on the tumor growth, different concentrations of anti-PD-L1-OX40 scFv antibody, reference antibody, or isotype antibody from 0.1-3 mg/kg will be administered intravenously twice weekly for 4 weeks in the mice after 14 days tumor cells implantation. The tumor growth will be measured twice per week up to 5 weeks as described in the Fox Chase SCID Beige mice model.

Example 7 Pharmacokinetic assessment of anti-PD-L1-OX40 scFv in mice and monkeys -40 mg / kg of bi-functional proteins, anti-PD-L1-OX40 scFv will be administered into mice or monkeys via subcutaneous injection or intravenous injection. Serum samples will be taken at different time points after the injection up to 15 days. Concentrations of the Fc fusion protein in the serum samples will be determined using a sandwiched ELISA assay.

Although the present invention has been described in considerable detail with reference to certain embodiments thereof, other embodiments are possible.

Therefore, the spirit and scope of the appended claims should not be limited to the description of the embodiments contained herein.

It will be apparent to those skilled in the art that various modifications and variations can be made to the structure of the present invention without departing from the scope or spirit of the invention. In view of the foregoing, it is intended that the present invention cover modifications and variations of this invention provided they fall within the scope of the following claims.

Claims (27)

WHAT IS CLAIMED IS:

1. An antibody or an antigen-binding portion thereof binding to OX40 (CD134), comprising: a heavy chain variable region comprising complementarity-determining regions (CDRs) CDR1, CDR2, and CDR3 set forth in the sequence of SEQ ID NO: 6 and a light chain variable region comprising CDR1, CDR2, and CDR3 set forth in amino acids 1-108 of SEQ ID NO: 5; a heavy chain variable region comprising CDR1, CDR2, and CDR3 set forth in the sequence of SEQ ID NO: 8 and a light chain variable region comprising CDR1, CDR2, and CDR3 set forth in amino acids 1-108 of SEQ ID NO: 7; a heavy chain variable region comprising CDR1, CDR2, and CDR3 set forth in amino acids 128-246 of SEQ ID NO: 10 and a light chain variable region comprising CDR1, CDR2, and CDR3 set forth in amino acids 1-112 of SEQ ID NO: 10; or a heavy chain variable region comprising CDR1, CDR2, and CDR3 set forth in amino acids 124-241 of SEQ ID NO: 13 and a light chain variable region comprising CDR1, CDR2, and CDR3 set forth in amino acids 1-108 of SEQ ID NO: 13.

2. The antibody or the antigen-binding portion thereof of claim 1, wherein the heavy chain variable region comprises a sequence that is at least 90% sequence identity to the sequence to SEQ ID NO: 6, and the light chain variable region comprises a sequence that is at least 90% sequence identity to the sequence to amino acids 1-108 of SEQ ID NO: 5, wherein the at least 90% sequence identity to the sequence to SEQ ID NO: 6 and amino acids 1-108 of SEQ ID NO: 5 excludes CDRs; wherein the heavy chain variable region comprises a sequence that is at least 90% sequence identity to the sequence to SEQ ID NO: 8, and the light chain variable region comprises a sequence that is at least 90% sequence identity to the sequence to amino acids 1-108 of SEQ ID NO: 7, wherein the at least 90% sequence identity to the sequence to SEQ ID NO: 8 and amino acids 1-108 of SEQ ID NO: 7 excludes CDRs; wherein the heavy chain variable region comprises a sequence that is at least 90% sequence identity to the sequence to amino acids 128-246 of SEQ ID NO: 10, and the light chain variable region comprises a sequence that is at least 90% sequence identity to the sequence to amino acids 1-112 of SEQ ID NO: 10, wherein the at least 90% sequence identity to the sequence to amino acids 128-246 of SEQ ID NO: 10 and amino acids 1-112 of SEQ ID NO: 10 excludes CDRs; wherein the heavy chain variable region comprises a sequence that is at least 90% sequence identity to the sequence to amino acids 124-241 of SEQ ID NO: 13, and the light chain variable region comprises a sequence that is at least 90% sequence identity to the sequence to amino acids 1-108 of SEQ ID NO: 13, wherein the at least 90% sequence identity to the sequence to amino acids 124-241 of SEQ ID NO: 13 and amino acids 1-108 of SEQ ID NO: 13 excludes CDRs.

3. The antibody or the antigen-binding portion thereof of claim 1, wherein the antibody or the antigen-binding portion thereof is a single chain variable fragment (scFv) sequence selected from the group consisting of SEQ ID NOs. 10, 11, 12, and 13.

4. The antibody or the antigen-binding portion thereof of claim 1, wherein the antibody or the antigen-binding portion thereof is a bispecific antibody.

5. The antibody or the antigen-binding portion thereof of claim 4, wherein the bispecific antibody comprises an immune checkpoint protein binding site.

6. The antibody or the antigen-binding portion thereof of claim 5, wherein the immune checkpoint protein binding site comprises a programmed cell death protein 1 ligand (PD-L1) binding site, PD-1 binding site, epidermal growth factor receptor (EGFR) binding site, human epidermal growth factor receptor 2 (HER2) binding site, cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) binding site, or lymphocyte activation gene 3 (LAG3) binding site.

7. An antibody or an antigen-binding portion thereof binding to PD-L1, comprising: a heavy chain variable domain comprising CDR1, CDR2, and CDR3 set forth in the sequence of SEQ ID NO: 2 and a light chain variable region comprising CDR1, CDR2, and CDR3 set forth in amino acids 1-111 of SEQ ID NO: 1; or a heavy chain variable domain comprising CDR1, CDR2, and CDR3 set forth in the sequence of SEQ ID NO: 4 and a light chain variable region comprising CDR1, CDR2, and CDR3 set forth in amino acids 1-110 of SEQ ID NO: 3.

8. The antibody or the antigen-binding portion thereof of claim 7, wherein the heavy chain variable region comprises a sequence that is at least 90% sequence identity to the sequence to SEQ ID NO: 2, and the light chain variable region comprises a sequence that is at least 90% sequence identity to the sequence to amino acids 1-111 of SEQ ID NO: 1, wherein the at least 90% sequence identity to the sequence to SEQ ID NO: 2 and amino acids 1-111 of SEQ ID NO: 1 excludes CDRs; wherein the heavy chain variable region comprises a sequence that is at least 90% sequence identity to the sequence to SEQ ID NO: 4, and the light chain variable region comprises a sequence that is at least 90% sequence identity to the sequence to amino acids 1-110 of SEQ ID NO: 3, wherein the at least 90% sequence identity to the sequence to SEQ ID NO: 4 and amino acids 1-110 of SEQ ID NO: 3 excludes CDRs.

9. A bispecific antibody comprising at least one of polypeptide chain, wherein the polypeptide chain comprises: an OX40 binding site according to claim 1 or 2; and a PD-L1 binding site according to claim 7 or 8.

10. The bispecific antibody of claim 9, wherein the polypeptide chain further comprises: a Fc domain; a Fab fragment connected to the N-terminus of the Fc domain, and the Fab fragment comprising the PD-L1 binding site; and a scFv connected to the C-terminus of the Fc domain, and the scFv comprising the OX40 binding site.

11. The bispecific antibody of claim 10, wherein the polypeptide chain further comprises a linker between the Fc domain and the scFv.

12. The bispecific antibody of claim 11, wherein the scFv comprises an amino acid sequence selected from the group consisting of amino acid 455-707 of SEQ ID NO: 18, 455-708 of SEQ ID NO: 19, 455-701 of SEQ ID NO: 20, 455-706 of SEQ ID NO: 21, 455-706 of SEQ ID NO: 22, 455-706 of SEQ ID NO: 23, 455-706 of SEQ ID NO: 24, 455-706 of SEQ ID NO: 25, 455-706 of SEQ ID NO: 26, 455-706 of SEQ ID NO: 27, 455-706 of SEQ ID NO: 28, and 455-706 of SEQ ID NO: 29.

13. The bispecific antibody of claim 9, wherein the bispecific antibody comprises one pairs of polypeptide chains.

14. The bispecific antibody of claim 13, wherein the bispecific antibody is an IgG, IgE, IgM, IgD, IgA, or IgY antibody.

15. The bispecific antibody of claim 14, wherein the bispecific antibody is an IgG antibody.

16. The bispecific antibody of claim 15, wherein the IgG antibody is an IgG1, IgG2, IgG3, or IgG4 antibody.

17. An antibody-drug conjugate comprising: a therapeutic agent; and the antibody or the antigen-binding portion thereof binding PD-L1 according to claim 7 or 8 and/or OX40 according to claim 1 or 2, wherein the therapeutic agent is covalently conjugated to the antibody or the antigen-binding portion thereof by a linker.

18. A pharmaceutical composition comprising the antibody or the antigen-binding portion thereof according to any one of claims 1 to 6, and at least one pharmaceutically acceptable carrier.

19. A pharmaceutical composition comprising the antibody or the antigen-binding portion thereof according to claim 7 or 8, and at least one pharmaceutically acceptable carrier.

20. A pharmaceutical composition comprising the bispecific antibody according to any one of claims 9 to 16, and at least one pharmaceutically acceptable carrier.

21. Use of the antibody or the antigen-binding portion thereof according to any one of claims 1 to 6 in the manufacture of a medicament for the treatment of cancer, wherein the cancer is selected from the group consisting of prostate cancer, kidney cancer, Non-Small Cell Lung Cancer (NSCLC), colon carcinoma, and renal cell carcinoma (RCC).

22. Use of the antibody or the antigen-binding portion according to claim 7 or 8 in the manufacture of a medicament for the treatment of cancer, wherein the cancer is selected from the group consisting of prostate cancer, kidney cancer, Non-Small Cell Lung Cancer (NSCLC), colon carcinoma, and renal cell carcinoma (RCC).

23. Use of the bispecific antibody according to any one of claims 9 to 16 in the manufacture of a medicament for the treatment of cancer, wherein the cancer is selected from the group consisting of prostate cancer, kidney cancer, Non-Small Cell Lung Cancer (NSCLC), colon carcinoma, and renal cell carcinoma (RCC).

24. A nucleic acid molecule encoding the antibody or the antigen-binding portion thereof according to any one of claims 1 to 6.

25. A nucleic acid molecule encoding the antibody or the antigen-binding portion thereof according to claim 7 or 8.

26. A nucleic acid molecule encoding the bispecific antibody according to any one of claims 9 to 16.

27. The antibody or the antigen-binding portion thereof according to claim 1 or 7, substantially as herein described with reference to any one of the examples and/or